Your browser doesn't support javascript.
loading
A phase II study of azacitidine in combination with granulocyte-macrophage colony-stimulating factor as maintenance treatment, after allogeneic blood or marrow transplantation in patients with poor-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Webster, Jonathan A; Yogarajah, Meera; Zahurak, Marianna; Symons, Heather; Dezern, Amy E; Gojo, Ivana; Prince, Gabrielle T; Morrow, Jillian; Jones, Richard J; Smith, B Douglas; Showel, Margaret.
Afiliación
  • Webster JA; Hematologic Malignancies and Bone Marrow Transplantation Program, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Yogarajah M; SSM Medical Group, St. Charles, MO, USA.
  • Zahurak M; Division of Biostatistics and Bioinformatics, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Symons H; Hematologic Malignancies and Bone Marrow Transplantation Program, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Dezern AE; Hematologic Malignancies and Bone Marrow Transplantation Program, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Gojo I; Hematologic Malignancies and Bone Marrow Transplantation Program, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Prince GT; Hematologic Malignancies and Bone Marrow Transplantation Program, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Morrow J; Hematologic Malignancies and Bone Marrow Transplantation Program, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Jones RJ; Hematologic Malignancies and Bone Marrow Transplantation Program, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Smith BD; Hematologic Malignancies and Bone Marrow Transplantation Program, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Showel M; Hematologic Malignancies and Bone Marrow Transplantation Program, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Leuk Lymphoma ; 62(13): 3181-3191, 2021 12.
Article en En | MEDLINE | ID: mdl-34284701
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Síndromes Mielodisplásicos / Leucemia Mieloide Aguda / Trasplante de Células Madre Hematopoyéticas Tipo de estudio: Diagnostic_studies / Etiology_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Leuk Lymphoma Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Síndromes Mielodisplásicos / Leucemia Mieloide Aguda / Trasplante de Células Madre Hematopoyéticas Tipo de estudio: Diagnostic_studies / Etiology_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Leuk Lymphoma Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos